

EFFECTIVE DATE: 10|01|2015
POLICY LAST UPDATED: 01|21|2020

OVERVIEW

This policy documents the coverage determination for use of immune cell function assays. Careful monitoring of lifelong immunosuppression is required to ensure long-term viability of solid organ allografts without incurring an increased risk of infection. The monitoring of immunosuppression parameters attempts to balance the dual risks of rejection and infection. It is proposed that individual immune profiles, such as an immune cell function assay, will help assess the immune function of the transplant recipient and individualize immunosuppressive therapy.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare

Use of the immune cell function assay to monitor and predict immune function after solid organ transplantation, hematopoietic stem-cell transplantation, and all other indications is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

Use of the immune cell function assay to monitor and predict immune function after solid organ transplantation, hematopoietic stem-cell transplantation, and all other indications is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

In current clinical practice, levels of immunosuppression in patients being managed after solid organ transplant or hematopoietic cell transplantation (HCT) are determined by testing for clinical toxicity (eg, leukopenia, renal failure) and by therapeutic drug monitoring when available. However, drug levels are not a surrogate for overall drug distribution or efficacy because pharmacokinetics often differ among individuals due to clinical factors such as underlying diagnosis, age, sex, and race; circulating drug levels may not reflect the drug concentration in relevant tissues; and serum level of an individual immunosuppressant drug may not reflect the cumulative effect of other concomitant immunosuppressants. The main value of therapeutic drug monitoring is the avoidance of toxic. Individual immune profiles, such as an immune cell function assay, could support clinical decision making and help to manage the risk of infection from excessive immunosuppression and the risk of rejection from inadequate immunosuppression.

Several commercially available tests of immune cell function have been developed to support clinical decision making.

ImmuKnow measures the concentration of adenosine triphosphate (ATP) in whole blood after a 15- to 18-hour incubation with phytohemagglutinin (a mitogenic stimulant). Cells that respond to stimulation show increased ATP synthesis during incubation. Concurrently, whole blood is incubated in the absence of stimulants for the purpose of assessing basal ATP activity. CD4 positive T lymphocytes are immunoselected from both samples using anti-CD4 monoclonal antibody-coated magnetic particles. After washing the selected CD4 positive cells on a magnet tray, a lysis reagent is added to release intracellular ATP. A luminescence reagent added to the released ATP produces light measured by a luminometer, which is proportional to the concentration of ATP. The characterization of the cellular immune response of a specimen is made by comparing the ATP concentration for that specimen with fixed ATP production ranges.

Pleximmune™ measures CD154 expression on T-cytotoxic memory cells in patient's peripheral blood lymphocytes. CD154 is a marker of inflammatory response. To characterize the risk of rejection, the patient's inflammatory response to (transplant) donor cells is expressed as a fraction of the patient's inflammatory response to third-party cells. This fraction or ratio is called the Immunoreactivity Index (IR). If the donor-induced response exceeds the response to third-party cells, the individual is at increased risk for rejection. Cells are cultured and then analyzed with fluorochrome-stained antibodies to identify the cells expressing CD154. For posttransplant blood samples, an IR greater than 1.1 indicates an increased risk of rejection, and an IR less than 1.1 indicates decreased risk of rejection. For pretransplant samples, the threshold for IR is 1.23.

Regulatory Status

In April 2002, ImmuKnow® (Cylex, acquired by ViraCor-IBT Laboratories, an immune cell function assay, was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The FDA-indicated use of ImmuKnow® is for the detection of cell-mediated immune response in populations undergoing immunosuppressive therapy for organ transplant.

In April 2002, Immune Cell Function Assay (Cylex) was cleared for marketing by FDA through the 510(k) process. The FDA-indicated use of the Immune Cell Function Assay is for the detection of cell-mediated immune response in an immunosuppressed population. In 2010, a device modification for this assay was cleared for marketing by FDA through the 510(k). There were no changes to the indications or intended use.

In August 2014, Pleximmune™ (Plexision) was approved by FDA through the humanitarian device exemption process. The test is intended for use in the pretransplantation and early and late posttransplantation period in pediatric liver and small bowel transplant patients for the purpose of predicting the risk of transplant rejection within 60 days after transplantation or 60 days after sampling.

For individuals who have a solid organ transplant or hematopoietic cell transplant who receive immune cell function assay testing with ImmuKnow, the evidence includes numerous studies on the association between assay test values and subsequent rejection or infection, and a randomized controlled trial in liver transplant patients. The relevant outcomes are overall survival, other test performance measures, and morbid events. The ImmuKnow test has shown variable associations with infection and rejection, depending on the type of transplant and context of the study. Across all the studies among various types of patients, ImmuKnow levels are associated with the risk of rejection when levels are high and risk of infection when levels are low. However, the absolute risk and increments of risk are uncertain because of the heterogeneity of the studies. The predictive characteristics of the test are still uncertain and do not allow a strong chain of evidence for clinical utility. The trial of the ImmuKnow test in liver transplant patients showed improvement in overall survival; however, the trial had several limitations. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have a solid organ transplant or hematopoietic cell transplant who receive immune cell function assay testing with Pleximmune, the evidence includes the U.S. Food and Drug Administration

documentation and a report on the test's development and validation. The relevant outcomes are overall survival, other measures of test performance, and morbid events. Small studies have shown that Pleximmune values correlate with long-term survival. Pleximmune test results correlated with rejection, but conclusions are uncertain because of extremely limited evidence deriving from a small number of patients described briefly in the Food and Drug Administration approval documents and a second study, in which the confidence interval bounds for sensitivity and specificity estimates were wide. No direct studies of clinical utility were identified. An argument for clinical utility using a chain of evidence would rely on both a demonstration of clinical validity and a rationale that specific clinical interventions based the results of the test decrease the risk of a poor health outcome. At present, the clinical interventions that would occur as a result of the test result are uncertain, and so the clinical validity is uncertain. The evidence is insufficient to determine the effects of the technology on health outcomes.

CODING

The following service is not covered for BlueCHiP for Medicare and considered not medically necessary for Commercial products:

86352 Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP)

RELATED POLICIES

Not applicable

PUBLISHED

Provider Update, March 2020

Provider Update, May 2019

Provider Update, Nov. /Dec. 2018

Provider Update, October 2017

Provider Update, January 2017

Provider Update, August 2015

REFERENCES

1. Food and Drug Administration (FDA). Special 510(k): Device Modification 2010 (K101911). n.d.; http://www.accessdata.fda.gov/cdrh_docs/reviews/K101911.pdf. Accessed November 11, 2019.
2. Food and Drug Administration (FDA). Summary of Safety and Probable Benefit: Pleximmune. 2014; http://www.accessdata.fda.gov/cdrh_docs/pdf13/H130004b.pdf. Accessed November 11, 2019.
3. Ling X, Xiong J, Liang W, et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. *Transplantation*. Apr 15 2012;93(7):737-743. PMID 22357178
4. Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow((R)) as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: Systematic review and meta-analysis. *Liver Transpl*. Jun 27 2012;18(10):1245-1253. PMID 22740321
5. Rossano JW, Denfield SW, Kim JJ, et al. Assessment of the Cylex ImmuKnow cell function assay in pediatric heart transplant patients. *J Heart Lung Transplant*. Jan 2009;28(1):26-31. PMID 19134527
6. Wong MS, Boucek R, Kemna M, et al. Immune cell function assay in pediatric heart transplant recipients. *Pediatr Transplant*. Aug 2014;18(5):485-490. PMID 24930882
7. Ryan CM, Chaudhuri A, Concepcion W, et al. Immune cell function assay does not identify biopsy-proven pediatric renal allograft rejection or infection. *Pediatr Transplant*. Aug 2014;18(5):446-452. PMID 24930482
8. Wozniak LJ, Venick RS, Gordon Burroughs S, et al. Utility of an immune cell function assay to differentiate rejection from infectious enteritis in pediatric intestinal transplant recipients. *Clin Transplant*. Feb 2014;28(2):229-235. PMID 24433466
9. Torio A, Fernandez EJ, Montes-Ares O, et al. Lack of association of immune cell function test with rejection in kidney transplantation. *Transplant Proc*. Jul-Aug 2011;43(6):2168-2170. PMID 21839223
10. Nishikawa K, Mizuno S, Masui S, et al. Usefulness of monitoring cell-mediated immunity for predicting post-kidney transplantation viral infection. *Transplant Proc*. Mar 2014;46(2):552-555. PMID 24656010

11. Sageshima J, Ciancio G, Chen L, et al. Lack of clinical association and effect of peripheral WBC counts on immune cell function test in kidney transplant recipients with T-cell depleting induction and steroid-sparing maintenance therapy. *Transpl Immunol*. Mar 2014;30(2-3):88-92. PMID 24518158
12. Reinsmoen NL, Cornett KM, Kloehn R, et al. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. *Transplantation*. Feb 15 2008;85(3):462-470. PMID 18301338
13. Serban G, Whittaker V, Fan J, et al. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. *Hum Immunol*. Nov 2009;70(11):882-890. PMID 19664673
14. Zhou H, Wu Z, Ma L, et al. Assessing immunologic function through CD4 T-lymphocyte adenosine triphosphate levels by Immuknow assay in Chinese patients following renal transplantation. *Transplant Proc*. Sep 2011;43(7):2574-2578. PMID 21911125
15. Huskey J, Gralla J, Wiseman AC. Single time point immune function assay (Immuknow) testing does not aid in the prediction of future opportunistic infections or acute rejection. *Clin J Am Soc Nephrol*. Feb 2011;6(2):423-429. PMID 21088287
16. Libri I, Gnappi E, Zanelli P, et al. Trends in immune cell function assay and donor-specific HLA antibodies in kidney transplantation: A 3-year prospective study. *Am J Transplant*. Dec 2013;13(12):3215-3222. PMID 24266972
17. Myslik F, House AA, Yanko D, et al. Preoperative Cylex assay predicts rejection risk in patients with kidney transplant. *Clin Transplant*. May 2014;28(5):606-610. PMID 24628326
18. Quaglia M, Cena T, Fenoglio R, et al. Immune function assay (immuknow) drop over first 6 months after renal transplant: a predictor of opportunistic viral infections? *Transplant Proc*. Sep 2014;46(7):2220-2223. PMID 25242755
19. Wang XZ, Jin ZK, Tian XH, et al. Increased intracellular adenosine triphosphate level as an index to predict acute rejection in kidney transplant recipients. *Transpl Immunol*. Jan 2014;30(1):18-23. PMID 24211610
20. Gupta S, Mitchell JD, Markham DW, et al. Utility of the Cylex assay in cardiac transplant recipients. *J Heart Lung Transplant*. Aug 2008;27(8):817-822. PMID 18656792
21. Shearer GM, Clerici M. In vitro analysis of cell-mediated immunity: clinical relevance. *Clin Chem*. Nov 1994;40(11 Pt 2):2162-2165. PMID 7955403
22. Jwa E, Hwang S, Kwon YJ, et al. In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients. *Korean J Hepatobiliary Pancreat Surg*. Nov 2015;19(4):139-148. PMID 26693232
23. Piloni D, Magni S, Oggionni T, et al. Clinical utility of CD4+ function assessment (ViraCor-IBT Immuknow test) in lung recipients. *Transpl Immunol*. Jul 2016;37:35-39. PMID 2709500
24. Ashokkumar C, Soltys K, Mazariegos G, et al. Predicting cellular rejection with a cell-based assay: preclinical evaluation in children. *Transplantation*. Jan 2017;101(1):131-140. PMID 26950712
25. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation*. Jun 2018;102(6):900-931. PMID 29596116

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

